drugset / Trial / NCT04018027
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to severe pruritus.
Timeline
- Start
- 2019-06-29
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Difelikefalin | Protein / enzyme biologic | 0.25 mg | Oral |
| Comparator | Difelikefalin | Protein / enzyme biologic | 0.5 mg | Oral |
| Comparator | Difelikefalin | Protein / enzyme biologic | 1 mg | Oral |